No CrossRef data available.
Article contents
Gender-affirming care in adolescents and young adults with cardiovascular conditions: clinical considerations in a limited evidence landscape
Published online by Cambridge University Press: 27 August 2025
Abstract
Gender-affirming care is a multi-faceted healthcare provided to transgender and gender diverse individuals to support their physical and mental health. As more adolescents and young adults may be interested in various gender care options, cardiologists should have familiarity with the medical and surgical therapies offered and the risk and considerations these may have, particularly for youth with the history of congenital or acquired cardiovascular disease. The existing literature on exogenous hormone therapy, for the general population and transgender individuals specifically, is by large limited to the adult population, with little relevant information for younger individuals. Current evidence indicates several potential cardiovascular implications to consider with gender-affirming hormone therapy without documented morbidity or clear contraindication for its use. These include the risk of thromboembolism, atherosclerotic and coronary artery disease, hypertension, and dyslipidemia among others. This review summarises existing evidence to assist in navigating the risks and therapeutic options so that offering gender-affirming care can be considered and delivered safely for adolescents and young adults with cardiovascular conditions and makes recommendations for future research.
Information
- Type
- Review
- Information
- Copyright
- © The Author(s), 2025. Published by Cambridge University Press
References
Herman, JL, Flores, AR, Brown, TNT, Wilson, BDM, Conron, KJ Age of individuals who identify as transgender in the United States. Williams Insitute. Available at Published 2017. Accessed Jan 2024. https://williamsinstitute.law.ucla.edu/wp-content/uploads/Age-Trans-Individuals-Jan-2017.pdf
Google Scholar
Herman, JL, Flores, AR, O’Neill, KK. How many adults and youth identify as transgender in the United States? Williams institute. Published 2022. Accessed Jan 2024. Available at: https://williamsinstitute.law.ucla.edu/publications/trans-adults-united-states/.Google Scholar
Cronin, B, Stockdale, CK. Health care for transgender and gender diverse individuals: American College of Obstetricians and Gynecologists Committee Opinion; 2021; 134-3:75–88.Google Scholar
APA. Guidelines for psychological practice with transgender and gender nonconforming people. Am Psychol 2015; 70: 832–864. DOI: 10.1037/a0039906.CrossRefGoogle Scholar
Coleman, E, Radix, AE, Bouman, WP, et al. Standards of care for the health of transgender and gender diverse people, version 8. Int J Transgend Health 2022; 23: S1–s259. DOI: 10.1080/26895269.2022.2100644.CrossRefGoogle ScholarPubMed
American Academy of Pediatrics. AAP reaffirms gender-affirming care policy, authorizes systematic review of evidence to guide update. Published August 4, 2023. Available at: https://www.aap.org/en/news-room/news-releases/aap/2023/american-academy-of-pediatrics-reaffirms-gender-affirming-care-policy-authorizes-systematic-review-of-evidence-to-guide-update/.Google Scholar
Rafferty, J, Yogman, M, Baum, R, et al. Ensuring comprehensive care and support for transgender and gender-diverse children and adolescents. Pediatrics 2018; 142: 1–14. doi:10.1542/peds.2018-2162.CrossRefGoogle ScholarPubMed
Hembree, WC, Cohen-Kettenis, PT, Gooren, L, et al. Endocrine treatment of gender-dysphoric/gender-incongruent persons: an endocrine society* clinical practice guideline. J Clin Endocrinol & Metab 2017; 102: 3869–3903. DOI: 10.1210/jc.2017-01658.CrossRefGoogle ScholarPubMed
van Zijverden, LM, Wiepjes, CM, van Diemen, JJK, Thijs, A, den Heijer, M. Cardiovascular disease in transgender people: a systematic review and meta-analysis. Eur J Endocrinol 2024; 190: S13–s24. DOI: 10.1093/ejendo/lvad170.CrossRefGoogle ScholarPubMed
Shawky, NM, Reckelhoff, JF, Alexander, BT, Yanes Cardozo, LL. Insights into the cardiomodulatory effects of sex hormones: implications in transgender care. Hypertension 2023; 80: 1810–1820. DOI: 10.1161/hypertensionaha.123.19501.CrossRefGoogle ScholarPubMed
Dutra, E, Lee, J, Torbati, T, Garcia, M, Merz, CNB, Shufelt, C. Cardiovascular implications of gender-affirming hormone treatment in the transgender population. Maturitas 2019; 129: 45–49. DOI: 10.1016/j.maturitas.2019.08.010.CrossRefGoogle ScholarPubMed
Streed, CG Jr., Beach, LB, Caceres, BA, et al. Assessing and addressing cardiovascular health in people who are transgender and gender diverse: a scientific statement from the american heart association. Circulation 2021; 144: e136–e148. DOI: 10.1161/cir.0000000000001003.CrossRefGoogle ScholarPubMed
Downing, JM, Przedworski, JM. Health of transgender adults in the U.S., 2014–2016. Am J Prev Med 2018; 55: 336–344. DOI: 10.1016/j.amepre.2018.04.045.CrossRefGoogle ScholarPubMed
Halperin, JL, Levine, GN, Al-Khatib, SM, et al. Further evolution of the ACC/AHA clinical practice guideline recommendation classification system: a report of the American college of cardiology/American heart association task force on clinical practice guidelines. J Am Coll Cardiol 2016; 67: 1572–1574. DOI: 10.1016/j.jacc.2015.09.001.CrossRefGoogle Scholar
Abou-Ismail, MY, Citla Sridhar, D, Nayak, L. Estrogen and thrombosis: a bench to bedside review. Thromb Res 2020; 192: 40–51. DOI: 10.1016/j.thromres.2020.05.008.CrossRefGoogle ScholarPubMed
Monagle, P, Cuello, CA, Augustine, C, et al. American society of hematology 2018 guidelines for management of venous thromboembolism: treatment of pediatric venous thromboembolism. Blood Adv 2018; 2: 3292–3316. DOI: 10.1182/bloodadvances.2018024786.CrossRefGoogle ScholarPubMed
Faraoni, D, Gardella, KM, Odegard, KC, Emani, SM, DiNardo, JA. Incidence and predictors for postoperative thrombotic complications in children with surgical and nonsurgical heart disease. Ann Thorac Surg 2016; 102: 1360–1367. DOI: 10.1016/j.athoracsur.2016.03.083.CrossRefGoogle ScholarPubMed
Hembree, WC, Cohen-Kettenis, P, Delemarre-van de Waal, HA, et al. Endocrine treatment of transsexual persons: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2009; 94: 3132–3154. DOI: 10.1210/jc.2009-0345.CrossRefGoogle ScholarPubMed
Scarabin, PY, Oger, E, Plu-Bureau, G. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet 2003; 362: 428–432. DOI: 10.1016/S0140-6736(03)14066-4.CrossRefGoogle ScholarPubMed
Arrington-Sanders, R, Connell, NT, Coon, D, et al. Assessing and addressing the risk of venous thromboembolism across the spectrum of gender affirming care: a review. Endocr Pract 2023; 29: 272–278. DOI: 10.1016/j.eprac.2022.12.008.Google ScholarPubMed
Arnold, JD, Sarkodie, EP, Coleman, ME, Goldstein, DA. Incidence of venous thromboembolism in transgender women receiving oral estradiol. J Sex Med 2016; 13: 1773–1777. DOI: 10.1016/j.jsxm.2016.09.001.CrossRefGoogle ScholarPubMed
Scheres, LJJ, Selier, NLD, Nota, NM, van Diemen, JJK, Cannegieter, SC, den Heijer, M. Effect of gender-affirming hormone use on coagulation profiles in transmen and transwomen. J Thromb Haemost 2021; 19: 1029–1037. DOI: 10.1111/jth.15256.CrossRefGoogle ScholarPubMed
Getahun, D, Nash, R, Flanders, WD, et al. Cross-sex hormones and acute cardiovascular events in transgender persons: a cohort study. Ann Intern Med 2018; 169: 205–213. DOI: 10.7326/m17-2785.CrossRefGoogle ScholarPubMed
Oakes, M, Arastu, A, Kato, C, et al. Erythrocytosis and thromboembolic events in transgender individuals receiving gender-affirming testosterone. Thromb Res 2021; 207: 96–98. DOI: 10.1016/j.thromres.2021.09.005.CrossRefGoogle ScholarPubMed
Tepper, NK, Whiteman, MK, Marchbanks, PA, James, AH, Curtis, KM. Progestin-only contraception and thromboembolism: a systematic review. Contraception 2016; 94: 678–700. DOI: 10.1016/j.contraception.2016.04.014.CrossRefGoogle ScholarPubMed
Cockrum, RH, Soo, J, Ham, SA, Cohen, KS, Snow, SG. Association of progestogens and venous thromboembolism among women of reproductive age. Obstet Gynecol 2022; 140: 477–487. DOI: 10.1097/aog.0000000000004896.CrossRefGoogle ScholarPubMed
Mullins, ES, Geer, R, Metcalf, M, et al. Thrombosis risk in transgender adolescents receiving gender-affirming hormone therapy. Pediatrics 2021; 147: 1–9. DOI: 10.1542/peds.2020-023549.CrossRefGoogle ScholarPubMed
Fedchenko, M, Mandalenakis, Z, Giang, KW, Rosengren, A, Eriksson, P, Dellborg, M. Long-term outcomes after myocardial infarction in middle-aged and older patients with congenital heart disease-a nationwide study. Eur Heart J 2021; 42: 2577–2586. DOI: 10.1093/eurheartj/ehaa874.CrossRefGoogle ScholarPubMed
Olsen, M, Marino, B, Kaltman, J, et al. Myocardial infarction in adults with congenital heart disease. Am J Cardiol 2017; 120: 2272–2277. DOI: 10.1016/j.amjcard.2017.08.050.CrossRefGoogle ScholarPubMed
de Ferranti, SD, Steinberger, J, Ameduri, R, et al. Cardiovascular risk reduction in high-risk pediatric patients: a scientific statement from the american heart association. Circulation 2019; 139: e603–e634. DOI: 10.1161/cir.0000000000000618.CrossRefGoogle ScholarPubMed
Hodis, HN, Mack, WJ, Henderson, VW, et al. Vascular effects of early versus late postmenopausal treatment with estradiol. N Engl J Med 2016; 374: 1221–1231. DOI: 10.1056/NEJMoa1505241.CrossRefGoogle ScholarPubMed
Harman, SM, Black, DM, Naftolin, F, et al. Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: a randomized trial. Ann Intern Med 2014; 161: 249–260. DOI: 10.7326/m14-0353.CrossRefGoogle ScholarPubMed
Alzahrani, T, Nguyen, T, Ryan, A, et al. Cardiovascular disease risk factors and myocardial infarction in the transgender population. Circ Cardiovasc Qual Outcomes 2019; 12: e005597. DOI: 10.1161/circoutcomes.119.005597.CrossRefGoogle ScholarPubMed
Vigen, R, ODonnell, CI, Barón, AE, et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. Jama 2013; 310: 1829–1836. DOI: 10.1001/jama.2013.280386.CrossRefGoogle ScholarPubMed
Finkle, WD, Greenland, S, Ridgeway, GK, et al. Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PLoS One 2014; 9: e85805. DOI: 10.1371/journal.pone.0085805.CrossRefGoogle ScholarPubMed
Basaria, S, Coviello, AD, Travison, TG, et al. Adverse events associated with testosterone administration. N Engl J Med 2010; 363: 109–122. DOI: 10.1056/NEJMoa1000485.CrossRefGoogle ScholarPubMed
Food and Drug Administration. FDA Drug Safety Communication. Published February 26, 2018. Accessed 1, 2025. https://www.fda.gov/drugs/drug-safety-and-availability/drug-safety-communications.Google Scholar
Baillargeon, J, Kuo, YF, Westra, JR, Urban, RJ, Goodwin, JS. Testosterone Prescribing in the United States, 2002-2016. Jama 2018; 320: 200–202. DOI: 10.1001/jama.2018.7999.CrossRefGoogle ScholarPubMed
Lincoff, AM, Bhasin, S, Flevaris, P, et al. Cardiovascular safety of testosterone-replacement therapy. N Engl J Med 2023; 389: 107–117. DOI: 10.1056/NEJMoa2215025.CrossRefGoogle ScholarPubMed
Morgentaler, A, Dhindsa, S, Dobs, AS, et al. Androgen society position paper on cardiovascular risk with testosterone therapy. Mayo Clin Proc 2024; 99: 1785–1801. DOI: 10.1016/j.mayocp.2024.08.008.CrossRefGoogle ScholarPubMed
Nota, NM, Wiepjes, CM, de Blok, CJM, Gooren, LJG, Kreukels, BPC, den Heijer, M. Occurrence of acute cardiovascular events in transgender individuals receiving hormone therapy. Circulation 2019; 139: 1461–1462. DOI: 10.1161/CIRCULATIONAHA.118.038584.CrossRefGoogle ScholarPubMed
Maraka, S, Singh Ospina, N, Rodriguez-Gutierrez, R, et al. Sex steroids and cardiovascular outcomes in transgender individuals: a systematic review and meta-analysis. J Clin Endocrinol Metab 2017; 102: 3914–3923. DOI: 10.1210/jc.2017-01643.CrossRefGoogle ScholarPubMed
Denby, KJ, Cho, L, Toljan, K, Patil, M, Ferrando, CA. Assessment of cardiovascular risk in transgender patients presenting for gender-affirming care. Am J Med 2021; 134: 1002–1008. DOI: 10.1016/j.amjmed.2021.02.031.CrossRefGoogle ScholarPubMed
Cocchetti, C, Castellini, G, Iacuaniello, D, et al. Does gender-affirming hormonal treatment affect 30-year cardiovascular risk in transgender persons? A two-year prospective european study (ENIGI). J Sex Med 2021; 18: 821–829. DOI: 10.1016/j.jsxm.2021.01.185.CrossRefGoogle ScholarPubMed
Greene, DN, Schmidt, RL, Christenson, RH, et al. Distribution of high-sensitivity cardiac troponin and n-terminal pro-brain natriuretic peptide in healthy transgender people. JAMA Cardiol 2022; 7: 1170–1174. DOI: 10.1001/jamacardio.2022.3299.CrossRefGoogle ScholarPubMed
Gulanski, BI, Flannery, CA, Peter, PR, Leone, CA, Stachenfeld, NS. Compromised endothelial function in transgender men taking testosterone. Clin Endocrinol (Oxf) 2020; 92: 138–144. DOI: 10.1111/cen.14132.CrossRefGoogle ScholarPubMed
Moudgal, R, Peritz, DC, Turco, J, Taub, C. Cardiac mechanics in altered hormonal states as a surrogate for understanding the effects of transgender hormone therapy. Cardiol Rev 2024; 32: 75–82. DOI: 10.1097/crd.0000000000000473.CrossRefGoogle ScholarPubMed
Duro, T, McClain, M, Aragon, KG, et al. Risk assessment and coronary artery calcium scoring in transgender and gender-diverse individuals receiving gender-affirming hormone therapy. Endocr Pract 2023; 29: 229–234. DOI: 10.1016/j.eprac.2022.12.007.CrossRefGoogle ScholarPubMed
Valentine, A, Nokoff, N, Bonny, A, et al. Cardiometabolic parameters among transgender adolescent males on testosterone therapy and body mass index-matched cisgender females. Transgend Health 2021; 6: 369–373. DOI: 10.1089/trgh.2020.0052.CrossRefGoogle ScholarPubMed
Valentine, A, Davis, S, Furniss, A, et al. Multicenter analysis of cardiometabolic-related diagnoses in transgender and gender-diverse youth: a pedsnet study. J Clin Endocrinol Metab 2022; 107: e4004–e4014. DOI: 10.1210/clinem/dgac469.CrossRefGoogle ScholarPubMed
Klaver, M, de Mutsert, R, van der Loos, M, et al. Hormonal treatment and cardiovascular risk profile in transgender adolescents. Pediatrics 2020; 145: 1–9. DOI: 10.1542/peds.2019-0741
CrossRefGoogle ScholarPubMed
Burns, JC, Shike, H, Gordon, JB, Malhotra, A, Schoenwetter, M, Kawasaki, T. Sequelae of Kawasaki disease in adolescents and young adults. J Am Coll Cardiol 1996; 28: 253–257. DOI: 10.1016/0735-1097(96)00099-x.CrossRefGoogle ScholarPubMed
Denby, KJ, Clark, DE, Markham, LW. Management of Kawasaki disease in adults. Heart 2017; 103: 1760–1769. DOI: 10.1136/heartjnl-2017-311774.CrossRefGoogle ScholarPubMed
Dionne, A, Ibrahim, R, Gebhard, C, et al. Difference between persistent aneurysm, regressed aneurysm, and coronary dilation in Kawasaki disease: an optical coherence tomography study. Can J Cardiol 2018; 34: 1120–1128. DOI: 10.1016/j.cjca.2018.05.021.Google ScholarPubMed
Montanez, N, Sexson Tejtel, SK, Menon, NM. Pediatric thromboprophylaxis of large coronary artery aneurysm using rivaroxaban. J Pediatr Hematol Oncol 2023; 45: 356–359. DOI: 10.1097/mph.0000000000002690.CrossRefGoogle ScholarPubMed
VanderPluym, C, Esteso, P, Ankola, A, et al. Real-world use of apixaban for the treatment and prevention of thrombosis in children with cardiac disease. J Thromb Haemost 2023; 21: 1601–1609. DOI: 10.1016/j.jtha.2023.03.005.CrossRefGoogle ScholarPubMed
Sagiv, E, Newland, DM, Slee, A, Olson, AK, Portman, MA. Real-world experience with edoxaban for anticoagulation in children at risk for coronary artery thrombosis. Cardiol Young 2024; 34:870–875. DOI: 10.1017/s1047951123003761.CrossRefGoogle Scholar
McCrindle, BW, Rowley, AH, Newburger, JW, et al. Diagnosis, treatment, and long-term management of Kawasaki disease: a scientific statement for health professionals from the american heart association. Circulation 2017; 135: e927–e999. DOI: 10.1161/cir.0000000000000484.CrossRefGoogle ScholarPubMed
Harrison, DJ, Prada, F, Nokoff, NJ, et al. Considerations for gender-affirming hormonal and surgical care among transgender and gender diverse adolescents and adults with congenital heart disease. J Am Heart Assoc 2024; 13: e031004. DOI: 10.1161/jaha.123.031004.CrossRefGoogle ScholarPubMed
Tsuda, E. Intervention in adults after Kawasaki disease. JACC Cardiovasc Interv 2016; 9: 697–699. DOI: 10.1016/j.jcin.2016.02.036.CrossRefGoogle ScholarPubMed
Costa, S, Saguner, AM, Gasperetti, A, Akdis, D, Brunckhorst, C, Duru, F. The link between sex hormones and susceptibility to cardiac arrhythmias: from molecular basis to clinical implications. Front Cardiovasc Med 2021; 8: 644279. DOI: 10.3389/fcvm.2021.644279.CrossRefGoogle ScholarPubMed
Grouthier, V, Moey, MYY, Gandjbakhch, E, et al. Sexual dimorphisms, anti-hormonal therapy and cardiac arrhythmias. Int J Mol Sci 2021; 22: 1464–1483. DOI: 10.3390/ijms22031464CrossRefGoogle ScholarPubMed
Wamboldt, R, Haseeb, S, Waddington, A, Baranchuk, A. Cardiac arrhythmias secondary to hormone therapy in trans women. Expert Rev Cardiovasc Ther 2019; 17: 335–343. DOI: 10.1080/14779072.2019.1606713.CrossRefGoogle ScholarPubMed
Zeller, T, Schnabel, RB, Appelbaum, S, et al. Low testosterone levels are predictive for incident atrial fibrillation and ischaemic stroke in men, but protective in women - results from the finrisk study. Eur J Prev Cardiol 2018; 25: 1133–1139. DOI: 10.1177/2047487318778346.CrossRefGoogle ScholarPubMed
Sichrovsky, TC, Mittal, S. Brugada syndrome unmasked by use of testosterone in a transgender male: gender trumps sex as a risk factor. J Innov Card Rhythm Manag 2019; 10: 3526–3529. DOI: 10.19102/icrm.2019.100202.CrossRefGoogle Scholar
Antwi-Amoabeng, D, Doshi, R, Adalja, D, et al. Burden of arrythmias in transgender patients hospitalized for gender-affirming surgeries. J Arrhythm 2020; 36: 797–800. DOI: 10.1002/joa3.12360.CrossRefGoogle ScholarPubMed
Waldner, RC, Doulla, M, Atallah, J, Rathwell, S, Grimbly, C. Leuprolide acetate and QTc interval in gender-diverse youth. Transgend Health 2023; 8: 84–88. DOI: 10.1089/trgh.2021.0102.CrossRefGoogle ScholarPubMed
Pediatric Endocrine Society Drug and Therapeutics Committee. Risk of Prolonged QT Interval with Gonadotropin Releasing Hormone Agonists. Pediatric Endocrine Society; 2017. Accessed 8, 2025. https://pedsendo.org/wp-content/uploads,2020/06/Risk_of_Prolonged_QT_Interval_with_GnRHa.pdf.Google Scholar
Almazan, AN, Keuroghlian, AS. Association between gender-affirming surgeries and mental health outcomes. JAMA Surg 2021; 156: 611–618. DOI: 10.1001/jamasurg.2021.0952.CrossRefGoogle ScholarPubMed
Hung, Y-C, Assi, PE, Park, BC, et al. Patterns of perioperative hormone therapy for gender-affirming surgery. Ann Plas Surg 2024; 92: 442–446. DOI: 10.1097/sap.0000000000003820.CrossRefGoogle ScholarPubMed
Price, R, Debryn, D, Mukerji, S, Nozari, A, Spiegel, JH, Kim, E. No thromboembolic complications after facial feminization surgery in transgender patients utilizing estrogen therapy: a retrospective cohort study. Transgend Health 2023; 8: 344–351. DOI: 10.1089/trgh.2021.0170.CrossRefGoogle ScholarPubMed
Snyder, L, Hebert, KJ, Horns, JJ, et al. Incidence and risk factors for postoperative venous thromboembolism after gender affirming vaginoplasty: a retrospective analysis of a large insurance claims database. Urology 2023; 182: 95–100. DOI: 10.1016/j.urology.2023.08.041.CrossRefGoogle ScholarPubMed
Nolan, IT, Haley, C, Morrison, SD, Pannucci, CJ, Satterwhite, T. Estrogen continuation and venous thromboembolism in penile inversion vaginoplasty. J Sex Med 2021; 18: 193–200. DOI: 10.1016/j.jsxm.2020.10.018.CrossRefGoogle ScholarPubMed
Badreddine, J, Lee, MH, Mishra, K, et al. Continuing perioperative estrogen therapy does not increase venous thromboembolic events in transgender patients: a systematic review and meta-analysis. Eur Rev Med Pharmacol Sci 2022; 26: 2511–2517. DOI: 10.26355/eurrev_202204_28488.Google Scholar
Robinson, IS, Rifkin, WJ, Kloer, C, et al. Perioperative hormone management in gender-affirming mastectomy: Is stopping testosterone before top surgery really necessary? Plast Reconstr Surg 2023; 151: 421–427. DOI: 10.1097/prs.0000000000009858.CrossRefGoogle ScholarPubMed
Wu, SS, Raymer, CA, Kaufman, BR, Isakov, R, Ferrando, CA. The effect of preoperative gender-affirming hormone therapy use on perioperative adverse events in transmasculine individuals undergoing masculinizing chest surgery for gender affirmation. Aesthet Surg J 2022; 42: 1009–1016. DOI: 10.1093/asj/sjac091.CrossRefGoogle ScholarPubMed
Wilson, W, Taubert, KA, Gewitz, M, et al. Prevention of infective endocarditis: guidelines from the American heart association: a guideline from the american heart association rheumatic fever, endocarditis, and Kawasaki disease committee, council on cardiovascular disease in the young, and the council on clinical cardiology, council on cardiovascular surgery and anesthesia, and the quality of care and outcomes research interdisciplinary working group. Circulation 2007; 116: 1736–1754. DOI: 10.1161/circulationaha.106.183095.CrossRefGoogle Scholar
Tutarel, O, Kempny, A, Alonso-Gonzalez, R, et al. Congenital heart disease beyond the age of 60: emergence of a new population with high resource utilization, high morbidity, and high mortality. Eur Heart J 2014; 35: 725–732. DOI: 10.1093/eurheartj/eht257.CrossRefGoogle ScholarPubMed
Jepson, A, Danford, D, Cramer, JW, Tsai, S, Yetman, AT. Assessment of hypertension, guideline-directed counseling, and outcomes in the ACHD population. Pediatr Cardiol 2022; 43: 1615–1623. DOI: 10.1007/s00246-022-02890-4.CrossRefGoogle ScholarPubMed
Greenberg, JH, Zappitelli, M, Devarajan, P, et al. Kidney outcomes 5 years after pediatric cardiac surgery: the TRIBE-AKI study. JAMA Pediatr 2016; 170: 1071–1078. DOI: 10.1001/jamapediatrics.2016.1532.CrossRefGoogle ScholarPubMed
Greenberg, JH, McArthur, E, Thiessen-Philbrook, H, et al. Long-term risk of hypertension after surgical repair of congenital heart disease in children. JAMA Network Open 2021; 4: e215237–e215237. DOI: 10.1001/jamanetworkopen.2021.5237.CrossRefGoogle ScholarPubMed
van Velzen, DM, Paldino, A, Klaver, M, et al. Cardiometabolic effects of testosterone in transmen and estrogen plus cyproterone acetate in transwomen. J Clin Endocrinol Metab 2019; 104: 1937–1947. DOI: 10.1210/jc.2018-02138.CrossRefGoogle ScholarPubMed
Banks, K, Kyinn, M, Leemaqz, SY, Sarkodie, E, Goldstein, D, Irwig, MS. Blood pressure effects of gender-affirming hormone therapy in transgender and gender-diverse adults. Hypertension 2021; 77: 2066–2074. DOI: 10.1161/hypertensionaha.120.16839.CrossRefGoogle ScholarPubMed
Pyra, M, Casimiro, I, Rusie, L, et al. An observational study of hypertension and thromboembolism among transgender patients using gender-affirming hormone therapy. Transgend Health 2020; 5: 1–9. DOI: 10.1089/trgh.2019.0061.CrossRefGoogle ScholarPubMed
Flynn, JT, Kaelber, DC, Baker-Smith, CM, et al. Clinical practice guideline for screening and management of high blood pressure in children and adolescents. Pediatrics 2017; 140: 1–72. DOI: 10.1542/peds.2017-1904.CrossRefGoogle ScholarPubMed
Stout, KK, Daniels, CJ, Aboulhosn, JA, et al. Aha/acc guideline for the management of adults with congenital heart disease: a report of the American college of cardiology/American heart association task force on clinical practice guidelines. J Am Coll Cardiol 2018; 73: e81–e192. DOI: 10.1016/j.jacc.2018.08.1029.CrossRefGoogle Scholar
Lindley, KJ, Bairey Merz, CN, Davis, MB, et al. Contraception and reproductive planning for women with cardiovascular disease: JACC focus seminar 5/5. J Am Coll Cardiol 2021; 77: 1823–1834. DOI: 10.1016/j.jacc.2021.02.025.CrossRefGoogle ScholarPubMed
American College of Gynecologists and Obstetrics Committee on Adolescent Health. Gynecologic considerations for adolescents and young women with cardiac conditions: ACOG committee opinion, number 813. Obstet Gynecol 2020; 136: e90–e99. DOI: 10.1097/AOG.0000000000004133.CrossRefGoogle Scholar
Ramzy, D, Rao, V, Brahm, J, Miriuka, S, Delgado, D, Ross, HJ. Cardiac allograft vasculopathy: a review. Can J Surg 2005; 48: 319–327. Published 2005/09/10.Google ScholarPubMed
Lange, V, Renner, A, Sagstetter, M, Harms, H, Elert, O. Cardiac allograft vasculopathy after cardiac transplantation and hormone therapy: positive effects? Transplantation 2006; 82: 234–240. DOI: 10.1097/01.tp.0000226179.16065.5e.CrossRefGoogle ScholarPubMed
Kobashigawa, LC, Hamilton, M, Rafiei, M, Stern, L, Bairey Merz, CN. Hormone therapy in women after heart transplantation. Transplant Proc 2013; 45: 3386–3388. DOI: 10.1016/j.transproceed.2013.06.011.CrossRefGoogle ScholarPubMed
Advocates for Trans Equality. Understanding transgender people: the basics. Accessed Jan 2024, https://transequality.org/issues/resources/understanding-transgender-people-the-basics
Google Scholar
Agostini et al. supplementary material 1
Agostini et al. supplementary material
File
18.1 KB
Agostini et al. supplementary material 2
Agostini et al. supplementary material
File
21 KB